Skip to Main Content

Paper Details

Mefloquine targets NLRP3 to reduce lipopolysaccharide-induced systemic inflammation and neural injury.
EMBO Rep
1
2023
LRR, Mefloquine, NACHT, NLR family, NLRP3, NLRP3 inflammasome, NLRP3-driven diseases, Parkinson's disease-like neural damage, human, mefloquine, mice, neural injury, pyrin domain containing 3, systemic inflammation
Author NameAffiliation
Tian TianNanjing Medical University
Tian TianNanjing Medical University
  • 1 - 2

Datasets

Release 1.2